商品名：Baytril
Fluoroquinolone antibacterial drug. Enrofloxacin acts via inhibition of DNA gyrase in bacteria to inhibit DNA and RNA synthesis. Enrofloxacin is a bactericidal with a broad spectrum of activity. In most animal species, enrofloxacin is metabolized to ciprofloxacin. Ciprofloxacin is an active desmethyl metabolite of enrofloxacin and may contribute in an additive fashion to the antibacterial effects. At the peak concentration, ciprofloxacin may account for approximately 10% and 20% of the total concentration in cats and dogs, respectively. Susceptible bacteria include Staphylococcus, Escherichia
Enrofloxacin, like other fluoroquinolones, is used to treat susceptible bacteria in a variety of species. Treatment has included infections of skin and soft tissue, UTIs in dogs and cats, Chlamydophila felis infections in cats, and and ulcerrative colitis caused by Escherichia coli in dogs. In horses it has been used for a variety of soft Enrofloxacin 279 E tissue infections and respiratory infections, although this use is based primarily on anecdotal experience. Enrofloxacin is approved for the treatment and control of swine respiratory disease (SRD) associated with Actinobacillus pleuropneum
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
腎功能調整：Patients with severe renal (or hepatic) impairment may require dosage adjustment to prevent drug accumulation.
腎功能調整：Patients with severe renal (or hepatic) impairment may require dosage adjustment to prevent drug accumulation.
腎功能調整：Patients with severe renal (or hepatic) impairment may require dosage adjustment to prevent drug accumulation.
腎功能調整：Patients with severe renal (or hepatic) impairment may require dosage adjustment to prevent drug accumulation.
核對活性部分、精確產品、劑型、強度、標籤版本與司法管轄區 核對物種、生產用途、診斷、感染部位、病原與感受性依據 核對視網膜、關節軟骨、神經、肝腎、胃腸與注射部位風險 核對所有併用藥、監測需求、法規限制與處方完整性
DRUGAPI 劑量審查引用的獸醫官方標示（各標示只適用於其產品、物種與法域，不可互換）
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。